{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:38:33Z","timestamp":1792013913320,"version":"4.4.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41584-026-01381-7","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:59:10Z","timestamp":1779379150000},"page":"459-470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treat-to-target in Beh\u00e7et syndrome"],"prefix":"10.1038","volume":"22","author":[{"given":"Alessandra","family":"Bettiol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5299-1406","authenticated-orcid":false,"given":"George","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5277-9229","authenticated-orcid":false,"given":"Aykut Ferhat","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-9611","authenticated-orcid":false,"given":"Rosaria","family":"Talarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u011fur","family":"Uyguno\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9575-8321","authenticated-orcid":false,"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclen","family":"Hatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"1381_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/rheumatology\/kew486","volume":"57","author":"C Maldini","year":"2018","unstructured":"Maldini, C., Druce, K., Basu, N., LaValley, M. P. & Mahr, A. Exploring the variability in Beh\u00e7et\u2019s disease prevalence: a meta-analytical approach. Rheumatology 57, 185\u2013195 (2018).","journal-title":"Rheumatology"},{"key":"1381_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/1744666X.2016.1205486","volume":"13","author":"F Davatchi","year":"2007","unstructured":"Davatchi, F. et al. Behcet\u2019s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev. Clin. Immunol. 13, 57\u201365 (2007).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"1381_CR3","first-page":"471","volume":"73","author":"JH Kappen","year":"2015","unstructured":"Kappen, J. H. et al. Beh\u00e7et\u2019s disease, hospital-based prevalence and manifestations in the Rotterdam area. Neth. J. Med. 73, 471\u2013477 (2015).","journal-title":"Neth. J. Med."},{"key":"1381_CR4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(23)02629-6","volume":"403","author":"G Emmi","year":"2024","unstructured":"Emmi, G., Bettio, I. A., Hatemi, G. & Prisco, D. Beh\u00e7et\u2019s syndrome. Lancet 403, 1093\u20131108 (2024).","journal-title":"Lancet"},{"key":"1381_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.713052","volume":"8","author":"I Mattioli","year":"2021","unstructured":"Mattioli, I., Bettio, I. A., Saruhan-Direskeneli, G., Direskeneli, H. & Emmi, G. Pathogenesis of Behcet\u2019s syndrome: genetic, environmental and immunological factors. Front. Med. 8, 713052 (2021).","journal-title":"Front. Med."},{"key":"1381_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2025.100293","volume":"11","author":"A Bettiol","year":"2025","unstructured":"Bettiol, A. et al. Epigenetic regulation of thrombo-inflammation in Beh\u00e7et and antiphospholipid syndrome. J. Transl. Autoimmun. 11, 100293 (2025).","journal-title":"J. Transl. Autoimmun."},{"key":"1381_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/annrheumdis-2021-220859","volume":"81","author":"G Emmi","year":"2022","unstructured":"Emmi, G. et al. A unique circulating miRNA profile highlights thrombo-inflammation in Beh\u00e7et\u2019s syndrome. Ann. Rheum. Dis. 81, 386\u2013397 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1381_CR8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1161\/CIRCRESAHA.120.317789","volume":"128","author":"G Emmi","year":"2021","unstructured":"Emmi, G. et al. Butyrate-rich diets improve redox status and fibrin lysis in Beh\u00e7et\u2019s syndrome. Circ. Res. 128, 278\u2013280 (2021).","journal-title":"Circ. Res."},{"key":"1381_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109304","volume":"250","author":"A Bettiol","year":"2023","unstructured":"Bettiol, A., Emmi, G., Low, L., Sofi, F. & Wallace, G. R. Microbiome in Behcet\u2019s syndrome. Clin. Immunol. 250, 109304 (2023).","journal-title":"Clin. Immunol."},{"key":"1381_CR10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1161\/CIRCULATIONAHA.115.017738","volume":"133","author":"M Becatti","year":"2016","unstructured":"Becatti, M. et al. Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Beh\u00e7et disease. Circulation 133, 302\u2013311 (2016).","journal-title":"Circulation"},{"key":"1381_CR11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/cei.13664","volume":"206","author":"A Bettiol","year":"2021","unstructured":"Bettiol, A. et al. Neutrophil-mediated mechanisms of damage and in-vitro protective effect of colchicine in non-vascular Behcet\u2019s syndrome. Clin. Exp. Immunol. 206, 410\u2013421 (2021).","journal-title":"Clin. Exp. Immunol."},{"key":"1381_CR12","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1136\/annrheumdis-2018-214335","volume":"78","author":"A Le Joncour","year":"2019","unstructured":"Le Joncour, A. et al. Critical role of neutrophil extracellular traps (NETs) in patients with Behcet\u2019s disease. Ann. Rheum. Dis. 78, 1274\u20131282 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1381_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.rdc.2023.03.010","volume":"49","author":"G Hatemi","year":"2023","unstructured":"Hatemi, G., U\u00e7ar, D., Uyguno\u011flu, U., Yazici, H. & Yazici, Y. Beh\u00e7et Syndrome. Rheum. Dis. Clin. North. Am. 49, 585\u2013602 (2023).","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"1381_CR14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1093\/rheumatology\/keh236","volume":"43","author":"G Mumcu","year":"2004","unstructured":"Mumcu, G. et al. Oral health is impaired in Beh\u00e7et\u2019s disease and is associated with disease severity. Rheumatology 43, 1028\u20131033 (2004).","journal-title":"Rheumatology"},{"key":"1381_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"International Team for the Revision","year":"2014","unstructured":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease The international criteria for Beh\u00e7et\u2019s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J. Eur. Acad. Dermatol. Venereol. 28, 338\u2013347 (2014).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1381_CR16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/acr.24511","volume":"74","author":"G Hatemi","year":"2022","unstructured":"Hatemi, G. et al. Core set of domains for outcome measures in Beh\u00e7et\u2019s syndrome. Arthritis Care Res. 74, 691\u2013699 (2022).","journal-title":"Arthritis Care Res."},{"key":"1381_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","volume":"364","author":"C Grigor","year":"2004","unstructured":"Grigor, C. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263\u2013269 (2004).","journal-title":"Lancet"},{"key":"1381_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152465","volume":"67","author":"Y Hao","year":"2024","unstructured":"Hao, Y., Oon, S. & Nikpour, M. Efficacy and safety of treat-to-target strategy studies in rheumatic diseases: a systematic review and meta-analysis. Semin. Arthritis. Rheum. 67, 152465 (2024).","journal-title":"Semin. Arthritis. Rheum."},{"key":"1381_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 75, 3\u201315 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1381_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82, 3\u201318 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1381_CR21","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1136\/ard.2007.071092","volume":"66","author":"SM Verstappen","year":"2007","unstructured":"Verstappen, S. M. et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann. Rheum. Dis. 66, 1443\u20131449 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"1381_CR22","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/rheumatology\/ker355","volume":"51","author":"I van Eijk","year":"2012","unstructured":"van Eijk, I. et al. Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatology 51, 686\u2013694 (2012).","journal-title":"Rheumatology"},{"key":"1381_CR23","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/annrheumdis-2013-203748","volume":"73","author":"Y Urata","year":"2014","unstructured":"Urata, Y., Nakamura, Y. & Furukawa, K. Comparison of initial versus delayed introduction of a treat-to-target strategy in patients with recent-onset rheumatoid arthritis: results of the T-4 3-year study. Ann. Rheum. Dis. 73, 470\u2013472 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1381_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/acr.23294","volume":"70","author":"RL Harrold","year":"2018","unstructured":"Harrold, R. L. et al. Cluster-Randomized trial of a behavioral intervention to incorporate a treat-to-target approach to care of US patients with rheumatoid arthritis. Arthritis Care Res. 70, 379\u2013387 (2018).","journal-title":"Arthritis Care Res."},{"key":"1381_CR25","first-page":"831","volume":"33","author":"CS Nair","year":"2015","unstructured":"Nair, C. S. et al. Economic evaluation of a tight-control treatment strategy using an imaging device (hand scan) for monitoring joint inflammation in early rheumatoid arthritis. Clin. Exp. Rheumatol. 33, 831\u2013838 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1381_CR26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/1471-2474-14-350","volume":"14","author":"M Vermeer","year":"2013","unstructured":"Vermeer, M. et al. Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. BMC Musculoskelet. Disord. 14, 350\u2013358 (2013).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1381_CR27","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","volume":"73","author":"RF van Vollenhoven","year":"2014","unstructured":"van Vollenhoven, R. F. et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann. Rheum. Dis. 73, 958\u2013967 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1381_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis, A. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann. Rheum. Dis. 83, 15\u201329 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1381_CR29","doi-asserted-by":"publisher","first-page":"103773","DOI":"10.1016\/j.autrev.2025.103773","volume":"24","author":"M Piga","year":"2025","unstructured":"Piga, M. et al. Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task force. Autoimmun. Rev. 24, 103773 (2025).","journal-title":"Autoimmun. Rev."},{"key":"1381_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","volume":"18","author":"AR Parra S\u00e1nchez","year":"2022","unstructured":"Parra S\u00e1nchez, A. R., Voskuyl, A. E. & van Vollenhoven, R. F. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat. Rev. Rheumatol. 18, 146\u2013157 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1381_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000221","volume":"2","author":"E Gvozdenovi\u0107","year":"2016","unstructured":"Gvozdenovi\u0107, E. et al. When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). RMD Open. 2, e000221 (2016).","journal-title":"RMD Open."},{"key":"1381_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.55563\/clinexprheumatol\/1lx7a5","volume":"132","author":"S Pirri","year":"2021","unstructured":"Pirri, S. et al. Adherence to treatment in Beh\u00e7et\u2019s syndrome: a multi-faceted issue. Clin. Exp. Rheumatol. 132, 88\u201393 (2021).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1381_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/BOR.0000000000000854","volume":"34","author":"G Hatemi","year":"2022","unstructured":"Hatemi, G. A treat-to-target approach is needed for Beh\u00e7et\u2019s syndrome. Curr. Opin. Rheumatol. 34, 39\u201345 (2022).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1381_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109186","volume":"246","author":"GE Fragoulis","year":"2023","unstructured":"Fragoulis, G. E. et al. Treat to target in Behcet\u2019s disease: should we follow the paradigm of other systemic rheumatic diseases? Clin. Immunol. 246, 109186 (2023).","journal-title":"Clin. Immunol."},{"key":"1381_CR35","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi, G. et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann. Rheum. Dis. 77, 808\u2013818 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1381_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2026.02.009","author":"G Hatemi","year":"2026","unstructured":"Hatemi, G. et al. EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome: 2025 update. Ann. Rheum. Dis. https:\/\/doi.org\/10.1016\/j.ard.2026.02.009 (2026).","journal-title":"Ann. Rheum. Dis."},{"key":"1381_CR37","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1136\/ard.2010.141234","volume":"70","author":"NB Klarenbeek","year":"2011","unstructured":"Klarenbeek, N. B. et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann. Rheum. Dis. 70, 1039\u20131046 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1381_CR38","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/rheumatology\/38.8.728","volume":"38","author":"BB Bhakta","year":"1999","unstructured":"Bhakta, B. B. et al. Beh\u00e7et\u2019s disease: evaluation of a new instrument to measure clinical activity. Rheumatology 38, 728\u2013733 (1999).","journal-title":"Rheumatology"},{"key":"1381_CR39","first-page":"532","volume":"23","author":"E Alpsoy","year":"2005","unstructured":"Alpsoy, E. Behcet\u2019s disease: treatment of mucocutaneous lesions. Clin. Exp. Rheumatol. 23, 532\u2013539 (2005).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1381_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.613432","volume":"7","author":"K Nakamura","year":"2020","unstructured":"Nakamura, K., Tsunemi, Y., Kaneko, F. & Alpsoy, E. Mucocutaneous manifestations of Behcet\u2019s disease. Front. Med. 7, 613432 (2020).","journal-title":"Front. Med."},{"key":"1381_CR41","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/930348","volume":"2014","author":"M Naito","year":"2014","unstructured":"Naito, M. et al. One-year period prevalence of oral aphthous ulcers and oral health-related quality of life in patients with Behcet\u2019s disease. Genet. Res. Int. 2014, 930348 (2014).","journal-title":"Genet. Res. Int."},{"key":"1381_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/451675","volume":"2015","author":"C Rotondo","year":"2015","unstructured":"Rotondo, C. et al. Mucocutaneous involvement in Behcet\u2019s disease: how systemic treatment has changed in the last decades and future perspectives. Mediators Inflamm. 2015, 451675 (2015).","journal-title":"Mediators Inflamm."},{"key":"1381_CR43","first-page":"43","volume":"35","author":"AA Senusi","year":"2017","unstructured":"Senusi, A. A., Ola, D., Mather, J., Mather, J. & Fortune, F. Behcet\u2019s syndrome and health-related quality of life: influence of symptoms, lifestyle and employment status. Clin. Exp. Rheumatol. 35, 43\u201350 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1381_CR44","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s11739-019-02046-y","volume":"14","author":"E Seyahi","year":"2019","unstructured":"Seyahi, E. Phenotypes in Behcet\u2019s syndrome. Intern. Emerg. Med. 14, 677\u2013689 (2019).","journal-title":"Intern. Emerg. Med."},{"key":"1381_CR45","first-page":"S80","volume":"32","author":"G Mumcu","year":"2014","unstructured":"Mumcu, G., Inanc, N., Taze, A., Ergun, T. & Direskeneli, H. A new mucocutaneous activity index for Behcet\u2019s disease. Clin. Exp. Rheumatol. 32, S80\u2013S86 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1381_CR46","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/j.1600-0714.2009.00803.x","volume":"38","author":"G Mumcu","year":"2009","unstructured":"Mumcu, G. et al. A composite index for determining the impact of oral ulcer activity in Behcet\u2019s disease and recurrent aphthous stomatitis. J. Oral. Pathol. Med. 38, 785\u2013791 (2009).","journal-title":"J. Oral. Pathol. Med."},{"key":"1381_CR47","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s00296-018-4117-y","volume":"38","author":"A Senusi","year":"2018","unstructured":"Senusi, A., Higgins, S. & Fortune, F. The influence of oral health and psycho-social well-being on clinical outcomes in Behcet\u2019s disease. Rheumatol. Int. 38, 1873\u20131883 (2018).","journal-title":"Rheumatol. Int."},{"key":"1381_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0341-7","volume":"10","author":"A Senusi","year":"2015","unstructured":"Senusi, A., Seoudi, N., Bergmeier, L. A. & Fortune, F. Genital ulcer severity score and genital health quality of life in Behcet\u2019s disease. Orphanet J. Rare Dis. 10, 117 (2015).","journal-title":"Orphanet J. Rare Dis."},{"key":"1381_CR49","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.semarthrit.2018.05.008","volume":"48","author":"P Leccese","year":"2019","unstructured":"Leccese, P. et al. Management of skin, mucosa and joint involvement of Behcet\u2019s syndrome: a systematic review for update of the EULAR recommendations for the management of Behcet\u2019s syndrome. Semin. Arthritis Rheum. 48, 752\u2013762 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"1381_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"A Arida","year":"2011","unstructured":"Arida, A., Fragiadaki, K., Giavri, E. & Sfikakis, P. P. Anti-TNF agents for Behcet\u2019s disease: analysis of published data on 369 patients. Semin. Arthritis Rheum. 41, 61\u201370 (2011).","journal-title":"Semin. Arthritis Rheum."},{"key":"1381_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet, H. et al. Efficacy of anti-TNF alpha in severe and\/or refractory Behcet\u2019s disease: Multicenter study of 124 patients. J. Autoimmun. 62, 67\u201374 (2015).","journal-title":"J. Autoimmun."},{"key":"1381_CR52","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/ard-2024-226113","volume":"84","author":"R Talarico","year":"2025","unstructured":"Talarico, R. et al. Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Beh\u00e7et\u2019s syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial. Ann. Rheum. Dis. 84, 504\u2013515\u00a0(2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1381_CR53","first-page":"98","volume":"32","author":"M Melikoglu","year":"2005","unstructured":"Melikoglu, M. et al. Short-term trial of etanercept in Behcet\u2019s disease: a double blind, placebo controlled study. J. Rheumatol. 32, 98\u2013105 (2005).","journal-title":"J. Rheumatol."},{"key":"1381_CR54","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","volume":"381","author":"G Hatemi","year":"2019","unstructured":"Hatemi, G. et al. Trial of apremilast for oral ulcers in Behcet\u2019s syndrome. N. Engl. J. Med. 381, 1918\u20131928 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 132","key":"1381_CR55","doi-asserted-by":"publisher","first-page":"80","DOI":"10.55563\/clinexprheumatol\/ra8ize","volume":"39","author":"G Hatemi","year":"2021","unstructured":"Hatemi, G. et al. Apremilast for oral ulcers associated with active Behcet\u2019s syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. Clin. Exp. Rheumatol. 39 (Suppl. 132), 80\u201387 (2021).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1381_CR56","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/rheumatology\/keae274","volume":"64","author":"G Lopalco","year":"2025","unstructured":"Lopalco, G. et al. Exploring relief for Behcet\u2019s disease refractory oral ulcers: a comparison of TNF inhibitors versus apremilast. Rheumatology. 64, 1302\u20131308 (2025).","journal-title":"Rheumatology."},{"key":"1381_CR57","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1080\/14397595.2020.1830504","volume":"31","author":"L Hirahara","year":"2021","unstructured":"Hirahara, L. et al. Efficacy and safety of apremilast for 3 months in Beh\u00e7et\u2019s disease: a prospective observational study. Mod. Rheumatol. 31, 856\u2013861 (2021).","journal-title":"Mod. Rheumatol."},{"key":"1381_CR58","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jaad.2021.11.045","volume":"87","author":"J London","year":"2022","unstructured":"London, J. et al. Efficacy and safety of ustekinumab in Behcet disease: results from the prospective phase 2 STELABEC trial. J. Am. Acad. Dermatol. 87, 681\u2013684 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1381_CR59","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/art.40912","volume":"71","author":"A Mirouse","year":"2019","unstructured":"Mirouse, A. et al. Long-term outcome of ustekinumab therapy for Behcet\u2019s disease. Arthritis Rheum. 71, 1727\u20131732 (2019).","journal-title":"Arthritis Rheum."},{"key":"1381_CR60","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jaut.2018.09.002","volume":"97","author":"G Di Scala","year":"2019","unstructured":"Di Scala, G. et al. Efficacy of the anti-IL 17 secukinumab in refractory Behcet\u2019s syndrome: a preliminary study. J. Autoimmun. 97, 108\u2013113 (2019).","journal-title":"J. Autoimmun."},{"key":"1381_CR61","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/annrheumdis-2020-217108","volume":"79","author":"F Fagni","year":"2020","unstructured":"Fagni, F. et al. Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behcet\u2019s phenotype: a multicentre study. Ann. Rheum. Dis. 79, 1098\u20131104 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1381_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-025-05806-6","volume":"45","author":"A Arida","year":"2025","unstructured":"Arida, A., Markomichelakis, N., Fragoulis, G. E. & Sfikakis, P. P. Very long-term remission in behcet\u2019s disease following withdrawal of anti-TNF treatment exceeds relapses: a reappraisal of an outcome study. Rheumatol. Int. 45, 60 (2025).","journal-title":"Rheumatol. Int."},{"key":"1381_CR63","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/ard.42.5.505","volume":"42","author":"S Yurdakul","year":"1983","unstructured":"Yurdakul, S. et al. The arthritis of Behcet\u2019s disease: a prospective study. Ann. Rheum. Dis. 42, 505\u2013515 (1983).","journal-title":"Ann. Rheum. Dis."},{"key":"1381_CR64","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1148\/radiol.2262011982","volume":"226","author":"JA Choi","year":"2003","unstructured":"Choi, J. A., Kim, J. E., Koh, S. H., Chung, H. W. & Kang, H. S. Arthropathy in Behcet disease: MR imaging findings in two cases. Radiology 226, 387\u2013389 (2003).","journal-title":"Radiology"},{"key":"1381_CR65","doi-asserted-by":"publisher","first-page":"W723","DOI":"10.2214\/AJR.12.8576","volume":"199","author":"F Ozkan","year":"2012","unstructured":"Ozkan, F. et al. Sonographic evaluation of subclinical entheseal involvement in patients with Behcet disease. Am. J. Roentgenol. 199, W723\u2013W729 (2012).","journal-title":"Am. J. Roentgenol."},{"key":"1381_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.626792","volume":"11","author":"M Vieira","year":"2021","unstructured":"Vieira, M. et al. Apremilast in refractory Beh\u00e7et\u2019s syndrome: a multicenter observational study. Front. Immunol. 11, 626792 (2021).","journal-title":"Front. Immunol."},{"key":"1381_CR67","doi-asserted-by":"publisher","unstructured":"Sevik, G. et al. The use of non-TNF targeted biologics in Beh\u00e7et\u2019s disease: real-life data from the international AIDA network Beh\u00e7et\u2019s disease registry. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/keag086 (2026).","DOI":"10.1093\/rheumatology\/keag086"},{"key":"1381_CR68","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/09273948.2017.1279840","volume":"25","author":"ET Cunningham Jr.","year":"2017","unstructured":"Cunningham, E. T. Jr. et al. Behcet uveitis. Ocul. Immunol. Inflamm. 25, 2\u20136 (2017).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1381_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113648","volume":"12","author":"M Joubert","year":"2023","unstructured":"Joubert, M. et al. Behcet\u2019s disease uveitis. J. Clin. Med. 12, 3648 (2023).","journal-title":"J. Clin. Med."},{"key":"1381_CR70","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/bjophthalmol-2017-311334","volume":"103","author":"A Alghamdi","year":"2019","unstructured":"Alghamdi, A. et al. Neuro-ophthalmological manifestations of Behcet\u2019s disease. Br. J. Ophthalmol. 103, 83\u201387 (2019).","journal-title":"Br. J. Ophthalmol."},{"key":"1381_CR71","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s11739-019-02248-4","volume":"15","author":"J Sota","year":"2020","unstructured":"Sota, J. et al. Beh\u00e7et\u2019s syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. Intern. Emerg. Med. 15, 1031\u20131039 (2020).","journal-title":"Intern. Emerg. Med."},{"key":"1381_CR72","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/03009742.2021.1904622","volume":"51","author":"M Torgutalp","year":"2022","unstructured":"Torgutalp, M. et al. Patient characteristics in Beh\u00e7et\u2019s syndrome and their associations with major organ involvement: a single-centre experience of 2118 cases. Scand. J. Rheumatol. 51, 50\u201358 (2022).","journal-title":"Scand. J. Rheumatol."},{"key":"1381_CR73","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3109\/09273948.2012.723112","volume":"20","author":"M Khairallah","year":"2012","unstructured":"Khairallah, M., Accorinti, M., Muccioli, C., Kahloun, R. & Kempen, J. H. Epidemiology of Beh\u00e7et disease. Ocul. Immunol. Inflamm. 20, 324\u2013335 (2012).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1381_CR74","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/00005792-200107000-00005","volume":"80","author":"B Bodaghi","year":"2001","unstructured":"Bodaghi, B. et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine 80, 263\u2013270 (2001).","journal-title":"Medicine"},{"key":"1381_CR75","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3109\/09273948.2015.1094095","volume":"25","author":"M Accorinti","year":"2017","unstructured":"Accorinti, M., Pesci, F. R., Pirraglia, M. P., Abicca, I. & Pivetti-Pezzi, P. Ocular Behcet\u2019s disease: changing patterns over time, complications and long-term visual prognosis. Ocul. Immunol. Inflamm. 25, 29\u201336 (2017).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1381_CR76","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.ajo.2011.05.032","volume":"152","author":"SR Taylor","year":"2011","unstructured":"Taylor, S. R. et al. Behcet disease: visual prognosis and factors influencing the development of visual loss. Am. J. Ophthalmol. 152, 1059\u20131066 (2011).","journal-title":"Am. J. Ophthalmol."},{"key":"1381_CR77","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.revmed.2018.02.022","volume":"39","author":"AC Desbois","year":"2018","unstructured":"Desbois, A. C., Terrada, C., Cacoub, P., Bodaghi, B. & Saadoun, D. [Ocular manifestations in Behcet\u2019s disease]. Rev. Med. Interne 39, 738\u2013745 (2018).","journal-title":"Rev. Med. Interne"},{"key":"1381_CR78","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/09273948.2016.1205100","volume":"25","author":"I Tugal-Tutkun","year":"2017","unstructured":"Tugal-Tutkun, I., Ozdal, P. C., Oray, M. & Onal, S. Review for diagnostics of the year: multimodal imaging in Behcet uveitis. Ocul. Immunol. Inflamm. 25, 7\u201319 (2017).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1381_CR79","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1080\/09273948.2025.2491568","volume":"33","author":"MJ Ghanbarnia","year":"2025","unstructured":"Ghanbarnia, M. J. et al. Association of optical coherence tomography angiography biomarkers with fluorescein angiography retinal inflammation scores in Behcet\u2019s retinal vasculitis. Ocul. Immunol. Inflamm. 33, 1534\u20131541 (2025).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1381_CR80","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/09273948.2022.2152700","volume":"32","author":"M Kabaalioglu Guner","year":"2024","unstructured":"Kabaalioglu Guner, M., Guner, M. E., Oray, M. & &Tugal-Tutkun, I. Correlation between widefield fundus fluorescein angiography leakage score and anterior chamber flare in Behcet Uveitis. Ocul. Immunol. Inflamm. 32, 54\u201356 (2024).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1381_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0323192","volume":"20","author":"M Mozafar","year":"2025","unstructured":"Mozafar, M. et al. OCTA measurements in Behcet\u2019s disease across different stages of the disease activity: a systematic review and meta-analysis. PLoS ONE 20, e0323192 (2025).","journal-title":"PLoS ONE"},{"key":"1381_CR82","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10384-013-0294-0","volume":"58","author":"T Kaburaki","year":"2014","unstructured":"Kaburaki, T. et al. Behcet\u2019s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J. Ophthalmol. 58, 120\u2013130 (2014).","journal-title":"Jpn J. Ophthalmol."},{"key":"1381_CR83","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/bjophthalmol-2015-307362","volume":"100","author":"R Tanaka","year":"2016","unstructured":"Tanaka, R. et al. Behcet\u2019s disease ocular attack score 24 and visual outcome in patients with Behcet\u2019s disease. Br. J. Ophthalmol. 100, 990\u2013994 (2016).","journal-title":"Br. J. Ophthalmol."},{"key":"1381_CR84","first-page":"1","volume":"2025","author":"M Erdag","year":"2025","unstructured":"Erdag, M. et al. Assessment of rheumatologists\u2019 perspectives on uveitis management: a cross-sectional nationwide survey. Ocul. Immunol. Inflamm. 2025, 1\u20138 (2025).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"1381_CR85","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","volume":"1","author":"K Masuda","year":"1989","unstructured":"Masuda, K. et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet\u2019s disease. Lancet 1, 1093\u20131096 (1989).","journal-title":"Lancet"},{"key":"1381_CR86","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici, H. et al. A controlled trial of azathioprine in Behcet\u2019s syndrome. N. Engl. J. Med. 322, 281\u2013285 (1990).","journal-title":"N. Engl. J. Med."},{"key":"1381_CR87","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"I Kotter","year":"2003","unstructured":"Kotter, I. et al. Human recombinant interferon alfa-2a for the treatment of Behcet\u2019s disease with sight threatening posterior or panuveitis. Br. J. Ophthalmol. 87, 423\u2013431 (2003).","journal-title":"Br. J. Ophthalmol."},{"key":"1381_CR88","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke, G. et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121, 785\u2013796.e3 (2014).","journal-title":"Ophthalmology"},{"key":"1381_CR89","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"PP Sfikakis","year":"2001","unstructured":"Sfikakis, P. P., Theodossiadis, P. G., Katsiari, C. G., Kaklamanis, P. & Markomichelakis, N. N. Effect of infliximab on sight-threatening panuveitis in Behcet\u2019s disease. Lancet 358, 295\u2013296 (2001).","journal-title":"Lancet"},{"key":"1381_CR90","doi-asserted-by":"publisher","first-page":"e780","DOI":"10.1016\/S2665-9913(24)00194-2","volume":"6","author":"Z Zhong","year":"2024","unstructured":"Zhong, Z. et al. Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Beh\u00e7et\u2019s disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial. Lancet Rheumatol. 6, e780\u2013e790 (2024).","journal-title":"Lancet Rheumatol."},{"key":"1381_CR91","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s10067-018-4092-4","volume":"37","author":"C Fabiani","year":"2018","unstructured":"Fabiani, C. et al. Predictors of sustained clinical response in patients with Behcet\u2019s disease-related uveitis treated with infliximab and adalimumab. Clin. Rheumatol. 37, 1715\u20131720 (2018).","journal-title":"Clin. Rheumatol."},{"key":"1381_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1095423","volume":"10","author":"M Takeuchi","year":"2023","unstructured":"Takeuchi, M. et al. Ten-year follow-up of infliximab treatment for uveitis in Beh\u00e7et disease patients: a multicenter retrospective study. Front. Med. 10, 1095423 (2023).","journal-title":"Front. Med."},{"key":"1381_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjo.2025.100261","volume":"14","author":"VTT Chan","year":"2025","unstructured":"Chan, V. T. T. et al. International consensuses and guidelines on managing ocular Beh\u00e7et\u2019s disease by the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO), the Asia-Pacific Vitreo-Retina Society (APVRS), the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII) and the Academia Retina Internationalis (ARI). Asia Pac. J. Ophthalmol. 14, 100261 (2025).","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"1381_CR94","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.2147\/OPTH.S524282","volume":"19","author":"M Almeida","year":"2025","unstructured":"Almeida, M., Ferreira, A. M., Araujo, J. R. & Figueira, L. Systemic immunomodulatory therapy in uveitis related to Behcet\u2019s disease: a 10-year profile. Clin. Ophthalmol. 19, 2133\u20132141 (2025).","journal-title":"Clin. Ophthalmol."},{"key":"1381_CR95","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1093\/brain\/122.11.2171","volume":"122","author":"G Akman-Demir","year":"1999","unstructured":"Akman-Demir, G., Serdaroglu, P. & Tas\u00e7i, B. Clinical patterns of neurological involvement in Beh\u00e7et\u2019s disease: evaluation of 200 patients. Brain 122, 2171\u20132182 (1999).","journal-title":"Brain"},{"key":"1381_CR96","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s004150170242","volume":"248","author":"A Siva","year":"2001","unstructured":"Siva, A. et al. Beh\u00e7et\u2019s disease: diagnostic and prognostic aspects of neurological involvement. J. Neurol. 248, 95\u2013103 (2001).","journal-title":"J. Neurol."},{"key":"1381_CR97","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444\u20131452 (1983).","journal-title":"Neurology"},{"key":"1381_CR98","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1007\/s00415-013-7209-3","volume":"261","author":"S Kalra","year":"2014","unstructured":"Kalra, S. et al. Diagnosis and management of Neuro-Beh\u00e7et\u2019s disease: international consensus recommendations. J. Neurol. 261, 1662\u20131676 (2014).","journal-title":"J. Neurol."},{"key":"1381_CR99","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","volume":"72","author":"DL Rotstein","year":"2015","unstructured":"Rotstein, D. L., Healy, B. C., Malik, M., Chitnis, T. & Weiner, H. L. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 72, 152\u2013158 (2015).","journal-title":"JAMA Neurol."},{"key":"1381_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117436","volume":"426","author":"U Uygunoglu","year":"2021","unstructured":"Uygunoglu, U. & Siva, A. An uncommon disease included commonly in the differential diagnosis of neurological diseases: Neuro-Beh\u00e7et\u2019s syndrome. J. Neurol. Sci. 426, 117436 (2021).","journal-title":"J. Neurol. Sci."},{"key":"1381_CR101","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11910-018-0843-5","volume":"18","author":"U Uygunoglu","year":"2018","unstructured":"Uygunoglu, U. & Siva, A. Beh\u00e7et\u2019s syndrome and nervous system involvement. Curr. Neurol. Neurosci. Rep. 18, 18\u201335 (2018).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"1381_CR102","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.55730\/1300-0144.5432","volume":"52","author":"Z Karaaslan","year":"2022","unstructured":"Karaaslan, Z. et al. Cerebrospinal fluid level of neurofilament light chain is associated with increased disease activity in neuro-Beh\u00e7et\u2019s disease. Turk. J. Med. Sci. 52, 1266\u20131273 (2022).","journal-title":"Turk. J. Med. Sci."},{"key":"1381_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.618973","volume":"11","author":"SN Esatoglu","year":"2020","unstructured":"Esatoglu, S. N. et al. Immunogenicity of infliximab among patients with Beh\u00e7et syndrome: a controlled study. Front. Immunol. 11, 618973 (2020).","journal-title":"Front. Immunol."},{"key":"1381_CR104","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000434684","volume":"90","author":"S Borekci","year":"2015","unstructured":"Borekci, S. et al. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-\u03b1 treatment. Respiration 90, 191\u2013198 (2015).","journal-title":"Respiration"},{"key":"1381_CR105","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41584-022-00880-7","volume":"19","author":"A Bettiol","year":"2023","unstructured":"Bettiol, A. et al. Vascular Beh\u00e7et syndrome: from pathogenesis to treatment. Nat. Rev. Rheumatol. 19, 111\u2013126 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1381_CR106","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41584-025-01252-7","volume":"21","author":"F Bello","year":"2025","unstructured":"Bello, F. et al. Arterial and venous thrombosis in systemic and monogenic vasculitis. Nat. Rev. Rheumatol. 21, 355\u2013369 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1381_CR107","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/MD.0b013e3182428f49","volume":"91","author":"G Geri","year":"2012","unstructured":"Geri, G. et al. Spectrum of cardiac lesions in Beh\u00e7et disease: a series of 52 patients and review of the literature. Medicine. 91, 25\u201334 (2012).","journal-title":"Medicine."},{"key":"1381_CR108","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1007\/s10067-025-07718-z","volume":"44","author":"D Hu","year":"2025","unstructured":"Hu, D. et al. Clinical features of cardiac and vascular involvements in Beh\u00e7et\u2019s syndrome: a cross-sectional study from Shanghai Beh\u00e7et\u2019s syndrome database. Clin. Rheumatol. 44, 5019\u20135028 (2025).","journal-title":"Clin. Rheumatol."},{"key":"1381_CR109","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1002\/art.34450","volume":"64","author":"AC Desbois","year":"2012","unstructured":"Desbois, A. C. et al. Immunosuppressants reduce venous thrombosis relapse in Beh\u00e7et\u2019s disease. Arthritis Rheum. 64, 2753\u20132760 (2012).","journal-title":"Arthritis Rheum."},{"key":"1381_CR110","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1002\/art.27568","volume":"62","author":"D Saadoun","year":"2010","unstructured":"Saadoun, D. et al. Mortality in Beh\u00e7et\u2019s disease. Arthritis Rheum. 62, 2806\u20132812 (2010).","journal-title":"Arthritis Rheum."},{"key":"1381_CR111","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi, E. et al. The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 82, 60\u201376 (2003).","journal-title":"Medicine"},{"key":"1381_CR112","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300354","volume":"3","author":"D Saadoun","year":"2024","unstructured":"Saadoun, D. et al. Infliximab versus cyclophosphamide for severe Beh\u00e7et\u2019s syndrome. NEJM Evid. 3, EVIDoa2300354 (2024).","journal-title":"NEJM Evid."},{"key":"1381_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109682","volume":"253","author":"G Hatemi","year":"2023","unstructured":"Hatemi, G. et al. Infliximab for vascular involvement in Beh\u00e7et\u2019s syndrome. Clin. Immunol. 253, 109682 (2023).","journal-title":"Clin. Immunol."},{"key":"1381_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-021-00193-5","volume":"61","author":"FT Elgengehy","year":"2021","unstructured":"Elgengehy, F. T. et al. Vasculitis damage index in Behcet\u2019s disease. Adv. Rheumatol. 61, 33 (2021).","journal-title":"Adv. Rheumatol."},{"key":"1381_CR115","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.jvs.2020.01.076","volume":"72","author":"J Gaudric","year":"2020","unstructured":"Gaudric, J. et al. Factors influencing the recurrence of arterial involvement after surgical repair in Behcet disease. J. Vasc. Surg. 72, 1761\u20131769 (2020).","journal-title":"J. Vasc. Surg."},{"key":"1381_CR116","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s10067-006-0530-9","volume":"26","author":"MC Park","year":"2007","unstructured":"Park, M. C., Hong, B. K., Kwon, H. M. & Hong, Y. S. Surgical outcomes and risk factors for postoperative complications in patients with Behcet\u2019s disease. Clin. Rheumatol. 26, 1475\u20131480 (2007).","journal-title":"Clin. Rheumatol."},{"key":"1381_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000003348","volume":"95","author":"I Hatemi","year":"2016","unstructured":"Hatemi, I. et al. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Beh\u00e7et\u2019s Syndrome: a strobe-compliant observational study from a dedicated multidisciplinary centre. Medicine 95, 1\u20138 (2016).","journal-title":"Medicine"},{"key":"1381_CR118","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00384-016-2728-x","volume":"32","author":"J Park","year":"2017","unstructured":"Park, J. et al. Risk factors and outcomes of acute lower gastrointestinal bleeding in intestinal Beh\u00e7et\u2019s disease. Int. J. Colorectal Dis. 32, 745\u2013751 (2017).","journal-title":"Int. J. Colorectal Dis."},{"key":"1381_CR119","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00054725-200108000-00010","volume":"7","author":"CR Lee","year":"2001","unstructured":"Lee, C. R., Kim, W. H. & Cho, Y. S. Colonoscopic findings in intestinal Beh\u00e7et\u2019s disease. Inflamm. Bowel Dis. 7, 243\u2013249 (2001).","journal-title":"Inflamm. Bowel Dis."},{"key":"1381_CR120","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.rdc.2017.09.007","volume":"44","author":"I Hatemi","year":"2018","unstructured":"Hatemi, I., Hatemi, G. & Celik, A. F. Gastrointestinal involvement in Beh\u00e7et\u2019s disease. Rheum. Dis. Clin. North. Am. 44, 45\u201364 (2018).","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"1381_CR121","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1038\/ajg.2009.331","volume":"104","author":"JH Cheon","year":"2009","unstructured":"Cheon, J. H. et al. Development and validation of novel diagnostic criteria for intestinal Beh\u00e7et\u2019s Disease in Korean patients with ileo-colonic ulcers. Am. J. Gastroenterol. 104, 2492\u20132499 (2009).","journal-title":"Am. J. Gastroenterol."},{"key":"1381_CR122","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1007\/s10620-009-1095-7","volume":"55","author":"CM Moon","year":"2010","unstructured":"Moon, C. M. et al. Prediction of free bowel perforation in patients with intestinal Beh\u00e7et\u2019s disease using clinical colonoscopic findings. Dig. Dis. Sci. 55, 2904\u20132911 (2010).","journal-title":"Dig. Dis. Sci."},{"key":"1381_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/S1873-9946(14)60380-9","volume":"8","author":"Y Erzin","year":"2014","unstructured":"Erzin, Y. et al. Comparative retrospective assessment of prospectively recorded endoscopic and histological findings between CD and GI-TBC; the first Eastern European registry data. J. Crohn\u2019s Colitis 8, S171 (2014).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"1381_CR124","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/jgh.16479","volume":"39","author":"K Murakami","year":"2024","unstructured":"Murakami, K. et al. Upper gastrointestinal involvement of Beh\u00e7et\u2019s disease in Japan: endoscopic findings and clinical features. J. Gastroenterol. Hepatol. 39, 708\u2013715 (2024).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1381_CR125","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3346\/jkms.2009.24.1.52","volume":"24","author":"SW Yi","year":"2009","unstructured":"Yi, S. W. et al. The prevalence and clinical characteristics of oesophageal involvement in patients with Beh\u00e7et\u2019s disease: a single centre experience in Korea. J. Korean Med. Sci. 24, 52\u201356 (2009).","journal-title":"J. Korean Med. Sci."},{"key":"1381_CR126","first-page":"145","volume":"33","author":"SN Esato\u011flu","year":"2015","unstructured":"Esato\u011flu, S. N. et al. A reappraisal of association between Beh\u00e7et\u2019s disease, myelodysplastic syndrome and trisomy 8: a systemic literature review. Clin. Exp. Rheumatol. 33, 145\u2013151 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1381_CR127","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1093\/rheumatology\/kead628","volume":"63","author":"A Burleight","year":"2024","unstructured":"Burleight, A. et al. Genetic testing of Beh\u00e7et\u2019s disease using next-generation sequencing to identify monogenetic mimics and HLA-B51. Rheumatology 63, 3457\u20133470 (2024).","journal-title":"Rheumatology"},{"key":"1381_CR128","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1016\/j.cgh.2021.03.021","volume":"20","author":"R Nambu","year":"2022","unstructured":"Nambu, R. et al. A systemic review of monogenetic inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 20, e653\u2013e663 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1381_CR129","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/ibd.21313","volume":"17","author":"JH Cheon","year":"2011","unstructured":"Cheon, J. H. et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Beh\u00e7et\u2019s disease. Inflamm. Bowel Dis. 17, 605\u2013613 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"1381_CR130","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s10620-014-3198-z","volume":"59","author":"SM Yim","year":"2014","unstructured":"Yim, S. M. et al. Mucosal healing predicts the long term prognosis of intestinal Beh\u00e7et\u2019s disease. Dig. Dis. Sci. 59, 2529\u20132535 (2014).","journal-title":"Dig. Dis. Sci."},{"key":"1381_CR131","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/jgh.13530","volume":"32","author":"DH Kim","year":"2017","unstructured":"Kim, D. H. et al. Faecal calprotectin as a non-invasive biomarker for intestinal involvement of Beh\u00e7et\u2019s disease. J. Gastroenterol. Hepatol. 32, 595\u2013601 (2017).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1381_CR132","first-page":"S90","volume":"36","author":"SN Esatoglu","year":"2018","unstructured":"Esatoglu, S. N. et al. Faecal but not serum calprotectin levels look promising in predicting active disease in Beh\u00e7et\u2019s syndrome patients with gastrointestinal involvement. Clin. Exp. Rheumatol. 36, S90\u2013S96 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1381_CR133","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00535-020-01690-y","volume":"55","author":"K Watanabe","year":"2020","unstructured":"Watanabe, K. et al. Evidence-based diagnosis and clinical practice guidelines for intestinal Beh\u00e7et\u2019s disease 2020 edited by intractable diseases, the health and labour sciences research grants. J. Gastroenterol. 55, 679\u2013700 (2020).","journal-title":"J. Gastroenterol."},{"key":"1381_CR134","doi-asserted-by":"publisher","first-page":"777","DOI":"10.5009\/gnl220278","volume":"17","author":"JH Cheon","year":"2023","unstructured":"Cheon, J. H. et al. Efficacy and safety of infliximab in intestinal Beh\u00e7et\u2019s disease: a multicentre, phase3 study (BEGIN). Gut Liver 17, 777\u2013785 (2023).","journal-title":"Gut Liver"},{"key":"1381_CR135","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3349\/ymj.2022.63.2.148","volume":"63","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. Efficacy and safety of anti-tumour necrosis factor-alpha agents for patients with intestinal Beh\u00e7et\u2019s disease: a systemic review and meta-analysis. Yonsei Med. J. 63, 148\u2013157 (2022).","journal-title":"Yonsei Med. J."},{"key":"1381_CR136","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13010247","volume":"13","author":"M Naganuma","year":"2025","unstructured":"Naganuma, M. et al. Assessment of IL-6, pathway inhibition in gastrointestinal Beh\u00e7et\u2019s disease from immunological and clinical perspectives. Biomedicines 13, 247 (2025).","journal-title":"Biomedicines"},{"key":"1381_CR137","first-page":"1","volume":"35","author":"FS Fousekis","year":"2022","unstructured":"Fousekis, F. S. et al. The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease. Ann. Gastroenterol. 35, 1\u20137 (2022).","journal-title":"Ann. Gastroenterol."},{"key":"1381_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109241","volume":"247","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. Baricitinib for the treatment of intestinal Beh\u00e7et\u2019s disease: a pilot study. Clin. Immunol. 247, 109241 (2023).","journal-title":"Clin. Immunol."},{"key":"1381_CR139","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221124014","volume":"14","author":"J Zou","year":"2022","unstructured":"Zou, J. et al. Tofacitinib as an alternative therapy for refractory intestinal Beh\u00e7et\u2019s syndrome. Ther. Adv. Musculoskelet. Dis. 14, 1759720 (2022).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"1381_CR140","first-page":"S129","volume":"33","author":"I Hatemi","year":"2015","unstructured":"Hatemi, I., Hatemi, G., Pamuk, O. N., Erzin, Y. & Celik, A. F. TNF-alpha antagonists and thalidomide for management of gastrointestinal Beh\u00e7et\u2019s syndrome refractory to conventional treatment modalities: a case series and review of the literature. Clin. Exp. Rheumatol. 33, S129\u2013S137 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1381_CR141","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/ibd.21517","volume":"17","author":"YS Jung","year":"2011","unstructured":"Jung, Y. S. et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Beh\u00e7et\u2019s disease. Inflamm. Bowel. Dis. 17, 1594\u20131602 (2011).","journal-title":"Inflamm. Bowel. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01381-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01381-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01381-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:02:23Z","timestamp":1782432143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01381-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":141,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1038\/s41584-026-01381-7","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"29 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.B. has received consulting fees from AbbVie, Alimera, Horus Pharma, Novartis and Roche. G.B. has received research grants, speaker fees and\/or consulting fees from MSD, AstraZeneca, GSK, AbbVie, Lilly, Boehringer, Ostuka and UCB. G.E. has received research grants, speaker fees and consulting fees from GSK, AstraZeneca, SOBI and Novartis. G.H. has received research grants, speaker fees and consulting fees from AbbVie, Amgen, Johnson & Johnson, MSD, Novartis, Soligenix and UCB Pharma. P.P.S. has received research grants, speaker fees and consulting fees from AbbVie, Amgen, Boehringer, Eli-Lilly, Elpen, Genesis, GSK, Johnson & Johnson, MSD, Novartis, Pfizer and UCB Pharma. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}